{
    "organizations": [],
    "uuid": "b7489520b2d3324dffba06a76af4953f14bef0d2",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-summit-therapeutics-says-muscle-da/brief-summit-therapeutics-says-muscle-damage-reduced-after-treatment-with-ezutromid-idUSASB0C2AY",
    "ord_in_thread": 0,
    "title": "BRIEF-Summit Therapeutics Says Muscle Damage Reduced After Treatment With Ezutromid",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 25 (Reuters) - Summit Therapeutics Plc:\n* EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS IN 24-WEEK INTERIM DATA FROM SUMMITâ€™S PHASEOUT DMD CLINICAL TRIAL\n* SUMMIT THERAPEUTICS - TREATMENT WITH EZUTROMID RESULTED IN A STATISTICALLY SIGNIFICANT AND MEANINGFUL REDUCTION IN MUSCLE DAMAGE\n* SUMMIT THERAPEUTICS - IN PHASEOUT DMD TRIAL, 14 OF 22 PATIENTS SHOWED DECREASE IN DEVELOPMENTAL MYOSIN, WITH 5 SHOWING OVER 40% REDUCTION\n* SUMMIT THERAPEUTICS - TOP-LINE RESULTS OF PHASEOUT DMD TRIAL EXPECTED TO BE REPORTED IN Q3 2018\n* SUMMIT THERAPEUTICS - TO CONDUCT RANDOMISED, PLACEBO CONTROLLED TRIAL TO SUPPORT ACCELERATED, CONDITIONAL APPROVAL OF EZUTROMID IN US, EU RESPECTIVELY Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-25T20:15:00.000+02:00",
    "crawled": "2018-01-26T21:37:45.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "summit",
        "therapeutic",
        "plc",
        "ezutromid",
        "significantly",
        "reduced",
        "muscle",
        "damage",
        "dmd",
        "patient",
        "interim",
        "data",
        "summit",
        "phaseout",
        "dmd",
        "clinical",
        "trial",
        "summit",
        "therapeutic",
        "treatment",
        "ezutromid",
        "resulted",
        "statistically",
        "significant",
        "meaningful",
        "reduction",
        "muscle",
        "damage",
        "summit",
        "therapeutic",
        "phaseout",
        "dmd",
        "trial",
        "patient",
        "showed",
        "decrease",
        "developmental",
        "myosin",
        "showing",
        "reduction",
        "summit",
        "therapeutic",
        "result",
        "phaseout",
        "dmd",
        "trial",
        "expected",
        "reported",
        "q3",
        "summit",
        "therapeutic",
        "conduct",
        "randomised",
        "placebo",
        "controlled",
        "trial",
        "support",
        "accelerated",
        "conditional",
        "approval",
        "ezutromid",
        "u",
        "eu",
        "respectively",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}